Symptom | Application route | Dosage (starting dose) | Indication |
---|---|---|---|
Pain | |||
Morphine | Subcutaneous, intravenous | 5–10 mg per bolus, 10–30 mg/day (or more) | Pain |
Hydromorphone | Subcutaneous, intravenous | 0.5–2 mg per bolus | Pain, dyspnoea |
Fentanyl | Transdermal | 12.5–400 µg/h (or more) | Stable pain |
Ibuprofen | Oral | 1200–2400 mg/day | Soft tissue pain or bone pain |
Dyspnoea | |||
Morphine | Subcutaneous, intravenous | 5–10 mg as bolus, 10–30 mg/day (or more) | Dyspnoea |
Lorazepam | Sublingual | 0.5–2.5 mg per bolus | Dyspnoea |
Scopolamine | Subcutaneous | 2–4 mg per bolus | Respiratory secretions |
Butylscopolamine | Subcutaneous | 20–40 mg per bolus | Respiratory secretions |
Nausea, vomiting | |||
Metoclopramide | Oral, subcutaneous, intravenous | 3×10 mg /day | Nausea, vomiting |
Haloperidol | Oral, subcutaneous, intravenous | 0.5–5 mg per bolus | Nausea, vomiting |
Gastrointestinal obstruction | |||
Octreotide | Subcutaneous | 50–500 µg/day | Excessive secretions in gastrointestinal tract |
Terminal restlessness, agitation | |||
Lorazepam | Sublingual | 1 mg | Anxiety, agitation, restlessness |
Midazolam | Subcutaneous, intravenous | 2.5–5 mg per bolus, 15–30 mg/day | Anxiety, agitation, restlessness |
Haloperidol (Haldol) | Oral, subcutaneous, intravenous | 2.5–5 mg per bolus up to 2×5 mg (or more) | Anxiety, agitation, restlessness |
Levomepromazine (Neurocil) | 25–50 mg bolus bis 200 mg/day | Anxiety, agitation, restlessness | |
Rescue medication | |||
Morphine | Subcutaneous | 10 mg | Pain, dyspnoea |
Butylscopolamine | Subcutaneous | 40 mg | Excessive secretions in respiratory tract or elsewhere |
Lorazepam | Sublingual | 1 mg | Anxiety, agitation, restlessness |
The list is an example; other medicines or application routes might be indicated, and other dose ranges might be indicated in selected patients. Additional information on essential medications in palliative care have been published by the International Association for Hospice and Palliative Care.10